Exclusion criteria: <br>Patients will be excluded from participation in the study if any of the following criteria apply:<br>1. Patients who require other lipid lowering treatments in addition to study drug (K-877) and statin<br>2. Patients with body mass index =40 kg/m2<br>3. Patients with homozygous familial hypercholesterolaemia (heterozygous is permitted) or familial hypoalphalipoproteinaemia<br>4. Patients with type 1 diabetes mellitus<br>5. Patients with poorly controlled type 2 diabetes mellitus (haemoglobin A1c >10%)<br>6. Patients who are receiving insulin or insulin analogue treatment except for stable basal insulin therapy with a single insulin<br>7. Patients with moderate or severe renal impairment (ie, estimated glomerular filtration rate <50 mL/min/1.73m2) at screening <br>8. Patients with serious liver dysfunction; liver function test values >3 × upper limit of normal (ULN) of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at screening <br>9. Patients with a creatine kinase level >3 × ULN at screening <br>10. Patients with hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormalities), gall bladder disease or pancreatitis<br>11. Patients with a history of drug or alcohol abuse; allowed amounts of alcohol are an average of 20 g for women and 30 g for men per day as consumed in the course of a week <br>12. Patients who have a hypersensitivity/intolerance to peroxisome proliferator-activated receptor a agonists or statins, or for whom statins are contraindicated as per approved statin SPC<br>13. Patients who had myocardial infarction, artery angioplasty, bypass graft surgery or severe/unstable angina pectoris within 3 months prior to screening<br>14. Patients who had symptomatic cerebrovascular disease including cerebrovascular haemorrhage, ischaemia (including transient ischaemic attack), or carotid endarterectomy within 3 months of screening<br>15. Patients with symptomatic heart failure (New York Heart Association class III or IV)<br>16. Patients who have uncontrolled hypertension (seated systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg); Note: An average of 3 readings within an adequate time interval during the study visit may be used to determine blood pressure level<br>17. Patients who have used lipid modifying treatment other than statins within the 28 days prior to screening<br>18. Patients with a history of chronic active hepatitis B or hepatitis C or known to be infected with human immunodeficiency virus (HIV) 1 or HIV 2<br>19. Patients with known muscular or neuromuscular disease<br>20. Patients with known active or history (<10 years from previous event) of neoplastic disease (excluding basal cell cancer) or patients who may need to take antineoplastic treatment during the study period<br>21. Patients with uncontrolled hypothyroidism or hyperthyroidism<br>Note: controlled thyroid disease (normal serum thyroid stimulating hormone [TSH] and stable therapy for at least 3 months) is permitted<br>22. Patients who have participated in any other clinical studies within 3 months of screening<br>23. Patients who have experienced a loss of more than 400 mL of blood during the 3 months prior to screening, eg, as a blood donor<br>24. Patients with a clinically relevant abnormal history, physical examination findings, 12 lead ECG, or laboratory values at screening that in the opinion of the investigator could interfere with the objectives of the study or the safety of the patient<br>25. Patients with a high p